Kyung Ah Yoh1, Ho Sup Lee2, Lee Chun Park1, Eun Mi Lee1, Seong Hoon Shin1, Dae Jin Park3, Byeong Jin Ye4, Yang Soo Kim1. 1. Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea. 2. Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea. Electronic address: hs3667@hanmail.net. 3. Department of Pharmacology, Kosin University College of Medicine, Busan, South Korea. 4. Department of Occupational and Environmental Medicine, Kosin University College of Medicine, Busan, South Korea.
Abstract
BACKGROUND: Elevated levels of serum ferritin have been documented to be an adverse prognostic factor in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The purpose of this study was to estimate the correlation between elevated levels of serum ferritin and survival outcomes in patients with non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: A total of 267 patients who were newly diagnosed with NHL and who received chemotherapy between September 1999 and April 2012 were retrospectively analyzed. RESULTS: In multivariate analysis, other chemotherapy regimens excluding CHOP-like chemotherapy regimens (cyclophosphamide, adriamycin, vincristine, prednisolone) and RCHOP (rituximab plus CHOP), a high level of β2-microglobulin, a high-intermediate/high risk according to the international prognostic index (IPI), and elevated levels of serum ferritin were all significant independent prognostic factors for 5-year progression-free survival rates. RCHOP and other chemotherapy regimens, a high level of β2-microglobulin, a high-intermediate/high IPI risk, and high levels of serum ferritin were significant independent prognostic factors for 5-year overall survival rates. CONCLUSION: Elevated levels of serum ferritin of 500 ng/mL or more as well as the use of chemotherapy regimens besides CHOP-like or RCHOP, a high-intermediate/high risk IPI, and a high level of beta2-microglobulin in NHL may be an important marker for predicting poor survival outcomes.
BACKGROUND: Elevated levels of serum ferritin have been documented to be an adverse prognostic factor in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The purpose of this study was to estimate the correlation between elevated levels of serum ferritin and survival outcomes in patients with non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: A total of 267 patients who were newly diagnosed with NHL and who received chemotherapy between September 1999 and April 2012 were retrospectively analyzed. RESULTS: In multivariate analysis, other chemotherapy regimens excluding CHOP-like chemotherapy regimens (cyclophosphamide, adriamycin, vincristine, prednisolone) and RCHOP (rituximab plus CHOP), a high level of β2-microglobulin, a high-intermediate/high risk according to the international prognostic index (IPI), and elevated levels of serum ferritin were all significant independent prognostic factors for 5-year progression-free survival rates. RCHOP and other chemotherapy regimens, a high level of β2-microglobulin, a high-intermediate/high IPI risk, and high levels of serum ferritin were significant independent prognostic factors for 5-year overall survival rates. CONCLUSION: Elevated levels of serum ferritin of 500 ng/mL or more as well as the use of chemotherapy regimens besides CHOP-like or RCHOP, a high-intermediate/high risk IPI, and a high level of beta2-microglobulin in NHL may be an important marker for predicting poor survival outcomes.
Authors: E J deAndrés-Galiana; J L Fernández-Martínez; O Luaces; J J Del Coz; R Fernández; J Solano; E A Nogués; Y Zanabilli; J M Alonso; A R Payer; J M Vicente; J Medina; F Taboada; M Vargas; C Alarcón; M Morán; A González-Ordóñez; M A Palicio; S Ortiz; C Chamorro; S Gonzalez; A P González-Rodríguez Journal: Clin Transl Oncol Date: 2015-04-21 Impact factor: 3.405
Authors: Da Jung Kim; Taeyun Kim; Jee-Yeong Jeong; Jae-Cheol Jo; Won Sik Lee; Ho-Jin Shin; Ji Hyun Lee; Ho Sup Lee Journal: Int J Hematol Date: 2020-01-06 Impact factor: 2.490